Chromogranin B in heart failure: A putative cardiac biomarker expressed in the failing myocardium

Circulation: Heart Failure

Volumn 3, Issue 4, 2010, Pages 503-511

  Røsjø, Helge ^a,b   Husberg, Cathrine ^b,c   Dahl, Mai Britt ^a,b   Stridsberg, Mats ^d   Sjaastad, Ivar ^b,c   Finsen, Alexandra Vanessa ^b,e   Carlson, Cathrine Rein ^b,c   Øie, Erik ^b,e   Omland, Torbjørn ^a,b   Christensen, Geir ^b,c  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d UPPSALA UNIVERSITY   (Sweden)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Biological markers; Chromogranin B; Heart failure; Molecular biology

Indexed keywords

ANGIOTENSIN II; BIOLOGICAL MARKER; CHROMOGRANIN A; CHROMOGRANIN B; NORADRENALIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE; HUMAN; LUNG WEIGHT; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BLOOD; CARDIOMYOPATHY; CASE CONTROL STUDY; COMPARATIVE STUDY; DISEASE COURSE; DISEASE MODEL; FOLLOW UP; HEART CONTRACTION; HEART FUNCTION TEST; HOSPITALIZATION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MORTALITY; NONPARAMETRIC TEST; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROBABILITY; RADIOIMMUNOASSAY; RANDOMIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL;

ANIMALS; BIOLOGICAL MARKERS; CARDIOMYOPATHIES; CASE-CONTROL STUDIES; CHROMOGRANIN B; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HEART FAILURE; HEART FUNCTION TESTS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MICE; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; PROBABILITY; RADIOIMMUNOASSAY; RANDOM ALLOCATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS;

EID: 77955507379     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.109.867747     Document Type: Article

References (42)

1. Velagaleti RS, Pencina MJ, Murabito JM, Wang TJ, Parikh NI, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation. 2008; 118:2057-2062.
2. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006;113:2335-2362.
3. Antman EM. Decision making with cardiac troponin tests. N Engl J Med. 2002;346:2079-2082.
4. Hama N, Itoh H, Shirakami G, Nakagawa O, Suga S, Ogawa Y, Masuda I, Nakanishi K, Yoshimasa T, Hashimoto Y. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation. 1995;92:1558-1564.
5. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358: 2148-2159.
6. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med. 2003;348:1134-1149.
7. O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptideproducing endocrine neoplasms. N Engl J Med. 1986;314:1145-1151.
8. Ceconi C, Ferrari R, Bachetti T, Opasich C, Volterrani M, Colombo B, Parrinello G, Corti A. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J. 2002;23: 967-974.
9. Omland T, Dickstein K, Syversen U. Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction. Am J Med. 2003;114:25-30.
10. Estensen ME, Hognestad A, Syversen U, Squire I, Ng L, Kjekshus J, Dickstein K, Omland T. Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. Am Heart J. 2006;152:927.e1- e6.
11. Jansson AM, Røsjø H, Omland T, Karlsson T, Hartford M, Flyvbjerg A, Caidahl K. Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J. 2009;30:25-32.
12. Pieroni M, Corti A, Tota B, Curnis F, Angelone T, Colombo B, Cerra MC, Bellocci F, Crea F, Maseri A. Myocardial production of chromo- granin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J. 2007;28:1117-1127.
13. Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut. 1996;39:649-653.
14. Stridsberg M, Eriksson B, Fellström B, Kristiansson G, Tiensuu JE. Measurements of chromogranin B can serve as a complement to chromogranin A. Regul Pept. 2007;139:80-83.
15. Steiner HJ, Weiler R, Ludescher C, Schmid KW, Winkler H. Chromogranins A and B are co-localized with atrial natriuretic peptides in secretory granules of rat heart. J Histochem Cytochem. 1990;38:845-850.
16. Iversen PO, Woldbæk PR, Tønnessen T, Christensen G. Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol Regul Integr Comp Physiol. 2002;282:R166-R172.
17. Finsen AV, Christensen G, Sjaastad I. Echocardiographic parameters discriminating myocardial infarction with pulmonary congestion from myocardial infarction without congestion in the mouse. J Appl Physiol. 2005;98:680-689.
18. Stridsberg M, Eriksson B, Ö berg K, Janson ET. A panel of 13 regionspecific radioimmunoassays for measurements of human chromogranin B. Regul Pept. 2005;125:193-199.
19. Stridsberg M, Eriksson B, Ö berg K, Janson ET. A panel of 11 regionspecific radioimmunoassays for measurements of human chromogranin A. Regul Pept. 2004;117:219-227.
20. Florholmen G, Andersson KB, Yndestad A, Austbø B, Henriksen UL, Christensen G. Leukaemia inhibitory factor alters expression of genes involved in rat cardiomyocyte energy metabolism. Acta Physiol Scand. 2004;180:133-142.
21. Mahata SK, Mahapatra NR, Mahata M, O'Connor DT. Neuroendocrine cell type-specific and inducible expression of chromogranin/secretogranin genes: crucial promoter motifs. Ann N Y Acad Sci. 2002;971: 27-38.
22. Heidrich FM, Zhang K, Estrada M, Huang Y, Giordano FJ, Ehrlich BE. Chromogranin B regulates calcium signaling, nuclear factor kappaB activity, and brain natriuretic peptide production in cardiomyocytes. Circ Res. 2008;102:1230-1238.
23. Huh YH, Jeon SH, Yoo SH. Chromogranin B-induced secretory granule biogenesis: comparison with the similar role of chromogranin A. J Biol Chem. 2003;278:40581-40589.
24. Pohl TM, Phillips E, Song KY, Gerdes HH, Huttner WB, Ruther U. The organisation of the mouse chromogranin B (secretogranin I) gene. FEBS Lett. 1990;262:219-224.
25. Minneman KP, Lee D, Zhong H, Berts A, Abbott KL, Murphy TJ. Transcriptional responses to growth factor and G protein-coupled receptors in PC12 cells: comparison of alpha(1)-adrenergic receptor subtypes. J Neurochem. 2000;74:2392-2400.
26. Muller FU, Neumann J, Schmitz W. Transcriptional regulation by cAMP in the heart. Mol Cell Biochem. 2000;212:11-17.
27. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
28. Lloyd RV, Cano M, Rosa P, Hille A, Huttner WB. Distribution of chromogranin A and secretogranin I (chromogranin B) in neuroendocrine cells and tumors. Am J Pathol. 1988;130:296-304.
29. Sekiya K, Ghatei MA, Salahuddin MJ, Bishop AE, Hamid QA, Ibayashi H, Polak JM, Bloom SR. Production of GAWK (chromogranin-B 420-493)-like immunoreactivity by endocrine tumors and its possible diagnostic value. J Clin Invest. 1989;83:1834-1842.
30. Saini SD, Schoenfeld P, Fendrick AM, Scheiman J. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention. Arch Intern Med. 2008; 168:1684-1690.
31. Stridsberg M, Ö berg K, Li Q, Engström U, Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol. 1995;144:49-59.
32. Stridsberg M, Husebye ES. Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma. Eur J Endocrinol. 1997;136:67-73.
33. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjølnerød OK, Waldum HL. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Prostate. 1997;30:1-6.
34. Jideus L, Ericson M, Stridsberg M, Nilsson L, Blomström P, Blomström- Lundqvist C. Diminished circadian variation in heart rate variability before surgery in patients developing postoperative atrial fibrillation. Scand Cardiovasc J. 2001;35:238-244.
35. Fung MM, Nguyen C, Mehtani P, Salem RM, Perez B, Thomas B, Das M, Schork NJ, Mahata SK, Ziegler MG, O'Connor DT. Genetic variation within adrenergic pathways determines in vivo effects of presynaptic stimulation in humans. Circulation. 2008;117:517-525.
36. Yoo SH, You SH, Kang MK, Huh YH, Lee CS, Shim CS. Localization of the secretory granule marker protein chromogranin B in the nucleus: potential role in transcription control. J Biol Chem. 2002;277: 16011-16021.
37. Kolodziejczyk SM, Wang L, Balazsi K, DeRepentigny Y, Kothary R, Megeney LA. MEF2 is upregulated during cardiac hypertrophy and is required for normal post-natal growth of the myocardium. Curr Biol. 1999;9:1203-1206.
38. Choe CU, Ehrlich BE. The inositol 1,4,5-trisphosphate receptor (IP3R) and its regulators: sometimes good and sometimes bad teamwork. Sci STKE. 2006;2006:re15.
39. Harzheim D, Movassagh M, Foo RSY, Ritter O, Tashfeen A, Conway SJ, Bootman MD, Roderick HL. Increased InsP3Rs in the junctional sarcoplasmic reticulum augment Ca2+ transients and arrhythmias associated with cardiac hypertrophy. Proc Natl Acad Sci U S A. 2009; 106:11406-11411.
40. Go LO, Moschella MC, Watras J, Handa KK, Fyfe BS, Marks AR. Differential regulation of two types of intracellular calcium release channels during end-stage heart failure. J Clin Invest. 1995;95:888-894.
41. Helle KB. The chromogranin A-derived peptides vasostatin-I and catestatin as regulatory peptides for cardiovascular functions. Cardiovasc Res. 2010;85:9-16.
42. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE Jr, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand SL, O'Donnell CJ, Smith SC Jr, Wilson PW. Criteria for Evaluation of Novel Markers of Cardiovascular Risk: a Scientific Statement from the American Heart Association. Circulation. 2009;119:2408-2416.